Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

News

2 Green Flags and 1 Red Flag for Novartis Stock
2 Green Flags and 1 Red Flag for Novartis Stock

Share prices of Swiss pharmaceutical company Novartis (NYSE: NVS) have climbed more than 10% so far this year. The company focuses on cardiovascular, immunology, neuroscience, solid tumors, and

Novartis Ag (NVS) Q3 2023 Earnings Call Transcript
Novartis Ag (NVS) Q3 2023 Earnings Call Transcript

Image source: The Motley Fool.

Novartis Ag (NYSE: NVS)Q3 2023 Earnings CallOct 24, 2023, 8:00 a.m. ET

Operator

Continue reading

Source Fool.com

2 Biotech Stocks That Could Make You Richer
2 Biotech Stocks That Could Make You Richer

Although sometimes risky and volatile, the biotech industry is an excellent place to find stocks that can generate steady returns for years. That's because these companies tend to offer products

3 Unstoppable Stocks to Buy and Hold for Decades
3 Unstoppable Stocks to Buy and Hold for Decades

Want to invest in stocks that you can buy and forget about? If so, you'll want to consider companies with plenty of long-term growth opportunities and solid financials. Among the best growth

2 Dividend Stocks to Buy and Hold Forever
2 Dividend Stocks to Buy and Hold Forever

Finding dividend stocks worth holding onto for good isn't an easy task. Investors shouldn't necessarily rely on a company's current dividend yield to make that decision. Recent history has shown

Could This Medicine Be the Next Winner for Novartis?
Could This Medicine Be the Next Winner for Novartis?

Earlier this month, the Switzerland-based pharmaceutical Novartis (NYSE: NVS) shared encouraging news from two phase 3 clinical trials of its drug candidate remibrutinib for a skin condition known

2 Top Biotech Stocks to Buy Right Now
2 Top Biotech Stocks to Buy Right Now

Income investing can be a great strategy for people looking to match their recurring bills with recurring dividend income. The trick is diversifying across top businesses in numerous industries to

2 Stocks That Raised Their Guidance in July
2 Stocks That Raised Their Guidance in July

One thing that can often drive up a stock's value is an increase in guidance. And two companies that recently boosted their projections for the year are Novartis (NYSE: NVS) and PepsiCo (NASDAQ:

Should Income Investors Buy This Blue Chip Stock?
Should Income Investors Buy This Blue Chip Stock?

For a dividend investor, generating enough income to become and stay financially independent (higher passive income than expenses) comes down in large part to the longevity of the businesses in an

Why Novartis Stock Spiked Today
Why Novartis Stock Spiked Today

Novartis (NYSE: NVS) enjoyed a strong rally today, as the Swiss drugmaker announced an improved revenue forecast for 2023 and a massive share repurchase program. Specifically, the drugmaker's stock

Novartis Ag (NVS) Q2 2023 Earnings Call Transcript
Novartis Ag (NVS) Q2 2023 Earnings Call Transcript

Image source: The Motley Fool.

Novartis Ag (NYSE: NVS)Q2 2023 Earnings CallJul 18, 2023, 8:00 a.m. ET

Operator

Continue reading

Source Fool.com

Why Novartis Stock Slipped on Friday
Why Novartis Stock Slipped on Friday

Pharmaceutical companies depend on the patent protection they receive for their goods, so it's never a good day when it is stripped away. That was the misfortune suffered by global pharmaceutical

Why Shares of Vera Therapeutics Jumped Tuesday
Why Shares of Vera Therapeutics Jumped Tuesday

Shares of Vera Therapeutics (NASDAQ: VERA) closed 16.9% higher on Tuesday after jumping as much as 23.5%. The clinical-stage biotech company announced positive news regarding trial results for one

Why Investors Should Care About Novartis' Latest Label Expansion -- It Could Mean Billions
Why Investors Should Care About Novartis' Latest Label Expansion -- It Could Mean Billions

Earlier this month, Novartis' (NYSE: NVS) smash-hit immunology medicine Cosentyx became the first drug within its class to be approved in the European Union to treat adult patients with moderate to

Why Shares of Chinook Therapeutics Skyrocketed On Monday
Why Shares of Chinook Therapeutics Skyrocketed On Monday

Shares of Chinook Therapeutics (NASDAQ: KDNY) were up more than 57% early Monday afternoon after the healthcare company agreed to a $3.2 billion buyout offer from Novartis. 

Chinook is a

Is Novartis a Good Stock to Buy Right Now?
Is Novartis a Good Stock to Buy Right Now?

Novartis (NYSE: NVS) is a company in transition. Over the past several years, the Swiss multinational pharma giant has been busy divesting key assets such as its eye care unit Alcon, trimming costs

Why Analog Devices Stock Was Down This Week
Why Analog Devices Stock Was Down This Week

Analog Devices (NASDAQ: ADI) shareholders lost ground to the market this week. The stock dropped 10% through Thursday trading, according to data provided by S&P Global Market Intelligence. That's

Why Shares of Rain Oncology Are Plummeting Today
Why Shares of Rain Oncology Are Plummeting Today

Shares of Rain Oncology (NASDAQ: RAIN) were down 87% Monday afternoon after the precision oncology company released top-line results for its lead therapy, milademetan, to treat dedifferentiated

Vifor Pharma nimmt Stellung zu Medienspekulationen
Vifor Pharma nimmt Stellung zu Medienspekulationen


Regulatory News:



AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR



Vifor führt mit CSL Gespräche über eine mögliche Transaktion. Entsprechende Entscheide sind noch nicht gefallen, es gibt

Lonza Nominates David Meline as Independent Board Member
Lonza Nominates David Meline as Independent Board Member
Lonza Nominates David Meline as Independent Board Member
Lonza Completes Acquisition of Large-Scale Biologics Site in Vacaville (US) from Roche
Lonza Completes Acquisition of Large-Scale Biologics Site in Vacaville (US) from Roche
Lonza Completes Acquisition of Large-Scale Biologics Site in Vacaville (US) from Roche
Lonza and Vertex Sign a Long-Term Commercial Supply Agreement for CASGEVY® (exagamglogene autotemcel)
Lonza and Vertex Sign a Long-Term Commercial Supply Agreement for CASGEVY® (exagamglogene autotemcel)
Lonza and Vertex Sign a Long-Term Commercial Supply Agreement for CASGEVY® (exagamglogene autotemcel)
Relief Therapeutics Completes Clinical Phase in RLF-OD032 Proof-of-Concept Study; Topline Results Expected in October 2024
Relief Therapeutics Completes Clinical Phase in RLF-OD032 Proof-of-Concept Study; Topline Results Expected in October 2024
Relief Therapeutics Completes Clinical Phase in RLF-OD032 Proof-of-Concept Study; Topline Results Expected in October 2024
Relief Therapeutics Announces PKU GOLIKE Study Results Presentation at SSIEM 2024
Relief Therapeutics Announces PKU GOLIKE Study Results Presentation at SSIEM 2024
Relief Therapeutics Announces PKU GOLIKE Study Results Presentation at SSIEM 2024
Relief Therapeutics Reports Half-Year 2024 Financial Results and Provides Corporate Update
Relief Therapeutics Reports Half-Year 2024 Financial Results and Provides Corporate Update
Relief Therapeutics Reports Half-Year 2024 Financial Results and Provides Corporate Update